• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Danaher (DHR) Using Buybacks to Reinforce Its Earnings Story Amid Slower Revenue Guidance?

    Simply Wall St·07/26/2026 22:20:24
    语音播报
    • Danaher Corporation recently reported second-quarter 2026 results showing higher sales of US$6,265 million and net income of US$870 million year over year, updated its third-quarter revenue growth guidance to about 2% to 3% including a respiratory testing headwind, and confirmed completion of several share repurchase tranches.
    • These updates highlight a company balancing rising earnings with more cautious near-term growth expectations, while deploying over US$4.79 billion on buybacks to reduce its share count.
    • With Danaher now guiding to modest third-quarter revenue growth that includes a respiratory testing headwind, we’ll examine how this reshapes its investment narrative.

    Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

    Danaher Investment Narrative Recap

    To own Danaher, you need to believe in steady demand for diagnostics and life science tools backed by recurring consumables and services. The key near term catalyst is how quickly core life science and diagnostics revenue can re-accelerate, while the biggest risk remains pressured bioprocessing and biotech funding. The latest quarter’s higher sales and earnings, plus modest Q3 revenue guidance of about 2% to 3% including a respiratory testing headwind, do not materially change that balance.

    Among the recent updates, Danaher’s completion of more than US$4.79 billion of share repurchases across its 2024 and 2025 programs stands out, especially with the share price down 16.9% year to date and analyst fair value estimates still above the current level. For investors tracking catalysts, this capital return sits alongside modest top line guidance and a more cautious core revenue outlook, keeping attention on how quickly underlying demand in life sciences and diagnostics can firm up.

    But against that backdrop, the pressure from weaker early stage biotech funding is something investors should be aware of because it...

    Read the full narrative on Danaher (it's free!)

    Danaher’s narrative projects $31.7 billion revenue and $6.9 billion earnings by 2029. This implies 8.0% yearly revenue growth and an earnings increase of about $2.9 billion from $4.0 billion today.

    Uncover how Danaher's forecasts yield a $228.61 fair value, a 19% upside to its current price.

    Exploring Other Perspectives

    DHR 1-Year Stock Price Chart
    DHR 1-Year Stock Price Chart

    Four Simply Wall St Community fair value estimates for Danaher span roughly US$187 to US$229 per share, underscoring how far opinions can stretch. Set this against Danaher’s muted near term revenue guidance and headwinds in bioprocessing, and you can see why it helps to compare several different views on what the business might deliver over time.

    Explore 4 other fair value estimates on Danaher - why the stock might be worth just $187.00!

    Reach Your Own Conclusion

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Interested In Other Possibilities?

    Every day counts. These free picks are already gaining attention. See them before the crowd does:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.